Novartis AG and Molecular Partners AG will halt recruitment of hospitalized COVID-19 patients in the ensovibep arm of the Phase III ACTIV-3 study after it failed a futility analysis. Their attentions now turn to the candidate’s potential in a non-hospitalized setting in another Phase II/III study, EMPATHY.
Molecular’s lead infectious disease candidate, ensovibep, did not meet the thresholds necessary to continue enrolment, the data and safety monitoring...